0000899243-20-025169.txt : 20200915
0000899243-20-025169.hdr.sgml : 20200915
20200915201221
ACCESSION NUMBER: 0000899243-20-025169
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200911
FILED AS OF DATE: 20200915
DATE AS OF CHANGE: 20200915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gros David-Alexandre C
CENTRAL INDEX KEY: 0001644489
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 201177127
MAIL ADDRESS:
STREET 1: 220 MARLBOROUGH STREET
STREET 2: #6
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Novus Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
BUSINESS PHONE: 949-238-8090
MAIL ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
FORMER COMPANY:
FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070622
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-11
0
0001404281
Novus Therapeutics, Inc.
NVUS
0001644489
Gros David-Alexandre C
C/O NOVUS THERAPEUTICS, INC.
19900 MACARTHUR BLVD., SUITE 550
IRVINE
CA
92612
1
1
0
0
Chief Executive Officer
Stock Option (Right to Buy)
500.00
2020-09-11
4
A
0
18278.14
0.00
A
2020-09-11
Series X1 Convertible Preferred Stock
18278.14
18278.14
D
This option represents a right to purchase a total of 18,278.14 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 13,708.605 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.
/s/ Ryan A. Murr, as attorney-in-fact for David-Alexandre Gros
2020-09-15